(18)F-fluoromethylcholine (FCho), (18)F-fluoroethyltyrosine (FET), and (18)F-fluorodeoxyglucose (FDG) for the discrimination between high-grade glioma and radiation necrosis in rats: a PET study.

@article{Bolcaen201518Ffluoromethylcholine,
  title={(18)F-fluoromethylcholine (FCho), (18)F-fluoroethyltyrosine (FET), and (18)F-fluorodeoxyglucose (FDG) for the discrimination between high-grade glioma and radiation necrosis in rats: a PET study.},
  author={Julie Bolcaen and Benedicte Descamps and Karel Deblaere and Tom Boterberg and Filip De Vos Pharm and J P O Kalala and Caroline M Van den Broecke and Elke Decrock and Luc Leybaert and Christian Vanhove and Ingeborg Goethals},
  journal={Nuclear medicine and biology},
  year={2015},
  volume={42 1},
  pages={38-45}
}
INTRODUCTION Discrimination between (high-grade) brain tumor recurrence and radiation necrosis (RN) remains a diagnostic challenge because both entities have similar imaging characteristics on conventional magnetic resonance imaging (MRI). Metabolic imaging, such as positron emission tomography (PET) could overcome this diagnostic dilemma. In this study, we investigated the potential of 2-[(18)F]-fluoro-2-deoxy-D-glucose ((18)F-FDG), O-(2-[(18)F]-fluoroethyl)-L-tyrosine ((18)F-FET), and [(18)F… CONTINUE READING